Method for prediction of clinical effectiveness of metformin and/or weight-loss therapy in patients with polycystic ovarian syndrome |
|
|
IPC classes for russian patent Method for prediction of clinical effectiveness of metformin and/or weight-loss therapy in patients with polycystic ovarian syndrome (RU 2427842):
Method of predicting risk of thyroid gland diseases in women of perimenopausal age / 2421127
Invention relates to field of medicine, namely to endocrinology. The following data are determined: cause of menopause, application of estrogen preparations, value of index of body weight and thyroid gland volume, concentration of antibodies to thyroid peroxidase and thyrotropic hormone. On the basis of obtained data prognostic coefficient which makes it possible to predict presence or absence of risk of developing thyroid gland diseases in the nearest five years is calculated.
 Method for prediction of developing metastases in patietns suffering rectal cancer / 2420742
Tissue samples of an tumour and perifocal regions are recovered from the preparation removed intraoperatively. They are analysed for the contents of prolactin and testosterone by radioimmunoassay. If the prolactin concentration is 692.0 ng/g of tissue, and the testosterone concentration is 48.0 ng/g of tissue in the tumour, while the testosterone concentration is 42.0 ng/g of tissue in the perifocal region, developing hepatic metastases are expected in 3 months. If the prolactin concentration is 160-390 ng/g of tissue, and the testosterone concentration is 20-40 ng/g of tissue in the tumour, while the testosterone concentration is 24-26 ng/g of tissue in the perifocal region, developing metastases are expected in 29-43 months.
 Diagnostic technique for function-type oddi's sphincter dyssynergia following cholecystectomy / 2416802
Cholecystokinin level is counted additionally in the patients with post-cholecystectomy syndrome. In case the concentration is below 0.5 ng/ml, and while observing no organic pathology of hepatopancreatoduodenal organs as demonstrated by instrument methods, function-type Oddi's sphincter dyssynergia is diagnosed.
Method of predicting duration of recurrence-free period in radically treated patients with mammary gland cancer / 2413231
Content of sex hormones -estradiol and progesterone - in blood is determined. After that coefficient of ratio of estradiol concentration to progesterone concentration is calculated. If values of coefficient are within the range from 10 to 221, duration of recurrence-free period from 5 to 13 years is predicted, and if values of coefficient are within the range 367-1295 recurrence-free period for 28-30 months is predicted.
Method of predicting of process activation in patients with hodgkin's lymphoma / 2405454
Invention relates to medicine, namely to biochemical investigations in oncology, and can be used in determination of activation or stabilisation of pathologic process in patients with primary-resistant Hodgkin's lymphoma. In patients with primary-resistant Hodgkin's lymphoma at stages of treatment, by radioimmune method determined is content in blood of thyroid gland hormones - triiodothyronine and thyroxine, and adrenocortical hormone - cortisol, their concentration is summed up and in case of total level of hormones is within 278.2 nmole/l - 0 333.0 nmole/l conclusion about activation of malignant process is made, if total level of said hormones is 432.4 nmole/l - 833.2 nmole/l conclusion about absence of process activation is made.
Diagnostic technique for severity level of varicocele and its recuring / 2403871
Invention refers to medicine, namely to urology and vascular surgery. The sex hormones level in an involved vein is considered to be a criterion of the severity level of varicocele. There are evaluated the following sex hormones: testosterone, estradiol, progesterone simultaneously in the pampiniform plexus veins of a left ovary and in the peripheral vein of a bend of elbow, with determining the ratio of the sex hormones level in a healthy vein of the bend of elbow to the varicocele-involved pampiniform plexus vein. If said ratio of the sex hormones level is 1:10 to 1:50, the first degree of varicocele is diagnosed. Recurrent varicocele and the second degree of varicocele is diagnosed by the ratio of the sex hormones level in the healthy and involved veins 1:50 to 1:100 times (i.e. hormones concentration in a varicose vein is increased in tens times). If observing the ratio of the sex hormones level in the healthy vein and the involved vein of the pampiniform plexus veins of the left ovary increasing more than in 1:100, the third degree of varicocele is diagnosed. Surgical intervention is indicated if the ratio of the sex hormones level is diagnosed more than 1:50.
 Method of bone resorption to remodelling analysis / 2403870
Invention refers to medicine, namely to biochemistry, surgery and dentistry. The bone resorption to remodeling analysis is based on the biochemical blood examination. An the blood coefficient K1 is calculated by formula: K1=[(PTH:A)+(TNF-α:B)+(IL-1β:C)]:3, where PTH is the parathyroid hormone concentration (pg/ml) in the patients, A is the same value in healthy individuals, TNF-α is the level of tumor necrosis factor -α (pg/ml) in the patients, B is the same value in healthy individuals, IL-1β is the interleukin-1β concentration (pg/ml) in the patients, C is the same value in healthy individuals to derive the blood coefficient K2 by formula: K2=[(calcitonin: D) + (osteocalcin: E)]:2, where the calcitonin concentration (ng/ml) in the patients, D is the same value in healthy individuals, the osteocalcin level (ng/ml) in the patients, E is the same value in healthy individuals. Then the bone metabolism control coefficient (BMCC) is calculated by formula BMCC=K1:K2, and the higher BMCC than 1.17, the more intensive resorption prevails over remodelling; and the lower BMCC than 0.83, the more intensive remodelling prevails over resorption.
Method for assessment of kidney function in felines by measurement of ghrelin hormone levels / 2403573
Method for assessment of kidney function in felines includes determination of observed level of ghrelin in tissue or biofluid of feline and establishment of direct dependence of observed level of ghrelin on kidney function by comparison of observed level of ghrelin with reference level of ghrelin that characterises normal kidney function. Method for diagnostics of kidney disease in felines includes detection of observed level of ghrelin in tissue or biofluid of feline and comparison of observed ghrelin level with referent level of ghrelin, which characterises normal kidney function, where observed level lower than reference level indicates kidney disease or predisposition to it. Method for detection of kidney disease beginning in felines includes monitoring level of ghrelin in tissue or biofluid of feline for a certain period of time; where beginning is identified, if at any moment of time level of ghrelin decreases compared to initial level that characterises healthy kidney function. Diagnostics set includes (a) one or more test materials to detect observed levels of ghrelin in tissue or biofluid of feline; and (b) one or more user-available mediums bearing the following information: (i) reference level of ghrelin that corresponds to a specific feline; and (ii) algorithm of direct dependence of observed ghrelin level relative to reference level on kidney function or reverse dependence of observed ghrelin level relative to reference level on availability of kidney disease or predisposition to kidney disease.
Diagnostic technique for foetal maturity / 2399058
There are determined daily excretion of progesterone metabolite - pregnandiol (Pd), foetal steroids - 16α-hydroxy-ethiocholanolone (16α-OH-Et), 16α-hydroxy-androsterone (16α-OH-An), 16α-hydroxy-dihydroepiandrosterone (16α-OH-DHEA) and oestradiol (Oe) in pregnant women on their 37-42 weeks of pregnancy by capillary gas chromatography. A mature foetus is indicated by the following indices: daily Pd excretion is 150.4-348.3 mcmol/24 hour, 16α-OH-Et - 7.9-16.9 mcmol/24 hour, 16α-OH-An - 6.4-12.6 mkmol/24 hour, 16α-OH-DHEA - 15.4-26.1 mcmol/24 hour, Oe - 24.0-38.7 mcmol/24 hour, while an immature foetus show the indices as follows: daily Pd excretion 80.1-150.2 mcmol/24 hour, 16α-OH-Et - 5.8-7.8 mcmol/24 hour, 16α-OH-An - 4.6-6.3 mcmol/24 hour, 16α-OH-DHEA - 10.2-15.3 mcmol/24 hour, and Oe - 14.5-15.6 mcmol/24 hour, and in a overmature foetus, daily Pd excretion, 16α-OH-Et, 16α-OH-An, 16α-OH-DHEA and Oe are considerably lowered and are less than 50.0 mcmol/24 hour, less than 12.0 mcmol/24 hour, less than 5.8 mcmol/24 hour, less than 4.6 mcmol/24 hour, less than 10.2 mcmol/24 hour, respectively.
Method for prediction of clinical course in disseminated skin melanoma patients / 2399057
Method is implemented by blood analysis for total and free triiodothyronine after the termination of integrated treatment to derive the total to free triiodothyronine ratio, and it is within the range 0.26-0.31, steady state is predicted to be kept in the patients; the ratio within the range 0.19-0.22 ensures to predict the disease generalisation. Technical and economic efficiency of the invention consists in the fact that the derived prognosis factor is an informative laboratory covariant of the favourable or unfavourable development of the pathology.
 Application of beta-hydroxybutyrate or its pharmaceutically acceptable salts for preparation of medication which possesses cytoprotective activity, including neuroprotective, cardioprotective, anti-ischemic, anti-hypoxic, anti-stress, actoprotective and adaptogenic activity, medication and method of prevention, relief and treatment by means of said medication / 2426535
Claimed is application of beta-hydroxybutyrate or its salts in combination with other active substance or combination of active substances, selected from group, given in the invention formula, for preparation of medication, which possesses cytoprotective activity, including neuroprotective, cardioprotective, anti-ischemic, antihypoxic, antistress and adaptogenic activities, medication and method of prevention, relief and treatment by means of said medication. Demonstrated is synergic of medication components as cytoprotector in urgent states as it possesses complex impact on key links of pathogenesis of said diseases.
Method of treating patients with neuropathic and neuroischemic forms of "diabetic foot" syndrome / 2425675
Invention relates to medicine, namely to endocrinology, and deals with treatment of patients with neuropathic and neuroischemic forms of "diabetic foot" syndrome. For this purpose at the first stage on both extremities injection of 0.25% Novocain is made in dose 50.0 ml into fascial compartment of common paroneal nerve in distal direction to upper musculo-peroneal canal. After 1-2 days as the second stage injections of 0.125% Novocain solution in amount 50.0 ml are repeated in turns into each extremity with interval 3-5 days, course containing 5-6 injections.
 Azepinoindole derivatives as pharmaceutical agents / 2423363
Invention refers to new compounds of formula (I):
 Method of correcting functions of vascular walls in patients with arterial hypertension of i-ii degree with metabolic syndrome after thrombosis of eye vessels / 2423126
Invention relates to medicine, namely to cardiology and angiology, and deals with correction of functions of vascular walls in patients with arterial hypertension of I-II degree with metabolic syndrome, after thrombosis of eye vessels. For this purpose indices of anti-aggregate, anti-coagulant and fibrinolytic activity of vascular wall are determined. On the basis of said indices calculated is total anti-thrombotic potential of vessels and if its value is 0.069 and lower, complex treatment, including application of individually selected hypocaloric diet, dosed physical load, pioglitazone 30 mg 1 time per day and valsartan 160 mg 1 time per day in the morning during 4 months, is administered.
 Method of evening-out dysfunctions of vascular wall in patients with arterial hypertension of iii degree with metabolic syndrome, after thrombosis of eye vessels / 2423125
Invention relates to medicine, namely to cardiology and angiology, and deals with correction of functions of vascular walls in patients with arterial hypertension of III degree with metabolic syndrome, after thrombosis of eye vessels. For this purpose indices of anti-aggregate, anti-coagulant and fibrinolytic activity of vascular wall are determined. On the basis of said indices calculated is total anti-thrombotic potential of vessels and if its value is 0.069 and lower, complex treatment, including application of individually selected hypocaloric diet, dosed physical load, pioglitazone 30 mg 1 time per day and valsartan 80 mg 1 time per day in the morning and amlodipine 10 mg 1 time per day during 4 months, is administered.
 Exenatid analogues / 2422461
Invention refers to new Exenatid analogues of general formula H-HisGlyGluGlyThrPheThrSerAspLeuSerLysGlnNleGluGluGluAlaValArgLeuPhe-IleGluTrpLeuLysAsnGlyGlyProSerSerGlyXProProProSer-ol where X is selected from L-Ala or D-Ala. The produced analogues show the stability higher than Exenatid, high insulinotropic activity, and also have high activity on renal sodition discharge without potassium ion loss, intensifis calcium and magnesium ion discharge, osmotically free water dishcarge. These properties can be effective for water-salt metabolism rebalancing along with glycemia normalisation.
 New phosphorus-containing thymomimetic drugs / 2422450
Present invention refers to compounds of formula VIII suitable in medicine as T3 mimetic drugs:
 Method of normalisation of functional activity of vessel wall in patients with arterial hypertension of i-ii degree with metabolic syndrome, after thrombosis of eye vessels / 2422141
Invention relates to medicine, namely to cardiology and angiology, and deals with normalisation of functional activity of vessel wall in patients with arterial hypertension of I-II degree with metabolic syndrome, after thrombosis of eye vessels. For this purpose, indices of anti-aggregation, anti-coagulation and fibrinolytic activity of vascular wall are determined. On the basis of said indices general anti-thrombotic potential of vessels is calculated and if its value is 0.069 and lower, administered is complex treatment, including application of individually selected hupocaloric diet, dosed physical load, introduction of pioglitazone in dose 30 mg 1 time per day and lisinopril in dose 20 mg 1 time per day for 4 months.
 Composition of biodegradable microspheres suitable for controlled release of glycose level-controlling peptide and its composition / 2422134
Invention relates to pharmacology and deals with method of obtaining microspheres from biodegradable polymer, including: addition of organic solvent to polymer, obtaining polymer solution (stage 1); dispersion of glucose level-regulating peptide in stage 1 polymer solution, obtaining medication dispersion and mixing alcohol or mixture of alcohol and organic acid with medication dispersion, obtaining solution with dispersed in it medication (stage 2); and obtaining microsphere from solution with dispersed in it stage 2 medication (stage 3), where glucose level-regulating peptide represents exedin-4 and where biodegradable polymer is selected from group, consisting of poly-L-lactic acid, D-lactic acid and glycolic acid copolymer, L-lactic acid and glycolic acid copolymer and D,L-lactic acid and glycolic acid copolymer.
 Oxadiazole compounds, use thereof in preparing medicinal agent and method of inhibiting dgat1 activity / 2421451
Invention relates to novel oxadiazole compounds of formula
 Derivatives of benzimidazole and pharmaceutical composition based on thereof / 2243968
Invention relates to new derivatives of benzimidazole represented by the following formula (I) or its salt:
|
FIELD: medicine. SUBSTANCE: patient is examined for an anti-Mueller hormone level. If its value is increased by 1/3 and less from an upper limit of normal, a positive menstrual response to treatment is predicted. EFFECT: method allows for high-precise prediction of clinical effectiveness of metformin and/or weight loss therapy in PCOS patients, exhibits high sensitivity and specificity. 4 ex
The invention relates to medicine, namely to endocrinology and gynecology, and can be used to predict the effectiveness of treatment of patients with polycystic ovary syndrome (PCOS) Metformin and/or weight loss. PCOS is a common endocrine disorder in women, a common cause of anovulatory infertility, oligomenorrhea and hirsutism. According to various sources it occurs in 5-10% of women of reproductive age. In a number of studies have shown that for these women is characterized by more frequent presence of insulin resistance than in the population, regardless of body mass index. Not less than 40% of women with PCOS are obese, and they are more insulinorezistentne than women of similar weight with normal ovarian function. There is a method of treatment of PCOS in women with excessive weight reducing weight. It helps reduce abdominal fat, insulin resistance and restore normal menstrual function (Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic discrimination in overweight women with polycystic ovary syndrome. J Clin Endocrinal Metab 2003; 88:812-9). There is a method of treatment of PCOS, including the use of drugs that increase insulin sensitivity, in particular of Metformin. This can help restore normal endocrinological the x and clinical parameters in women with PCOS by reducing insulin secretion (Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327:951). According to many studies, Metformin therapy decreases the level of luteinizing hormone, testosterone, to increase the regularity of the menstrual cycle, the frequency of spontaneous ovulation and pregnancy. There is a limited number of works which explore possible predictors of the effectiveness of weight loss and Metformin therapy in restoring ovulation. Known work, in which as prognostic indicators of successful weight loss and Metformin therapy in restoring ovulation described a high level of insulin resistance (Eisenhardt S. Early Effects of Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Endocrinol &Metab. 2006. Vol.91, No.3, 946-952), insulin, low Androstenedione and less severe menstrual irregularities (Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M 2000 Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85:139-146). However, in the known methods there is no quantitative criteria for predicting menstrual response in individual patients. The technical result achieved by the invention is to improve the accuracy of predicting the effectiveness of treatment Bollnas PCOS Metformin and/or weight loss through the use of quantitative criteria forecasting. The invention consists in the achievement of the stated technical result in the method for predicting the effectiveness of treatment of patients with polycystic ovary syndrome Metformin and/or weight loss, according to which the patient determine the level antimullerian hormone and increasing by no more than 1/3 from the top border of norm predict positive menstrual response to treatment. The method is based on the results of the authors conducted a clinical study of the efficiency of weight reduction and/or treatment with Metformin in relation to the menstrual response in women with PCOS. The study included 38 women with PCOS. The average age of the group was 25±0,8 years, body mass index (BMI) of 27.0±,2 kg/m2(18-39 kg/m2). 12 women had normal weight (BMI 18-24,2 kg/m2average of 20.6±2.2 kg/m2) and received treatment with Metformin (group a). 26 women were overweight or obese (BMI 25-39 kg/m2average of 30.9±4.9 kg/m2). 13 of them were randomized to lifestyle change (group B), but one of them to lose weight have failed, and she was prescribed Metformin. Thirteen other patients in addition to lifestyle modification was assigned to Metformin (group b). Of these four women managed to reduce the weight. Thus was formed a group of 5 women with excess ve the Ohm, received therapy Metformin without changing the weight (group D). After completion of treatment in patients with PCOS were divided into 2 groups: women, in whom therapy was obtained menstrual response in the form of increasing the number of menstrual cycles, the occurrence of ovulation, pregnancy and women who have not received this response. Menstrual response was obtained in 21 patients, which accounted for 55% of the entire group with PCOS: 4 women with a regular cycle and chronic anovulation recovered ovulation (3 of them recorded pregnancy) and 17 women (sixteen with oligomenorrhea and one with amenorrhea) increased number of menstrual cycles over 6 months of treatment. In 8 of them appeared ovulation and 3 of them is pregnancy. Just ovulation was observed in 11 patients (29%) and in 6 of them were observed pregnancy (15.8% of all treated women). Patients responding and not responding to treatment, did not differ significantly on baseline characteristics. In the group of responders and non-response to treatment of women with PCOS are respectively the average age (25.8 vs. 26.7 years), mean BMI (27.8 vs. 28.7 kg/m2), the average waist circumference (88.4 against the 90.8 cm), average hirsute number (9.9 vs. 10.2 points) and the average number of menstrual cycles for 6 months prior to treatment, (2.9 vs. 2.5) were similar. GRU is dust source was not different and the main hormonal parameters. Only the original share, on which groups significantly differed, was AMG, which was significantly lower in the group of the respondents (6,3±3.4 ng/ml)than non-response to treatment (9,8±4.5 ng/ml), p=0.043. Was also recruited a control group of 50 healthy women without menstrual disorders and signs of hyperandrogenemia, which determined the level of AMH. The range of standards was adopted interquartile scale values of AMH in the control group. He was 2.28-6,09 ng/ml. Using discriminate analysis and ROC curves were calculated value AMG with the optimal combination of sensitivity and specificity for predicting menstrual answer. It was 8.1 ng/ml, sensitivity 81,3%, a specificity of 61.5%. Thus, if the AMH level in the patient is less of 8.1 ng/ml or increased by no more than 1/3 from the top border of norm, it is possible to predict a positive menstrual response to treatment PCOS aimed at reducing insulin resistance through weight loss and/or Metformin. The method is carried out, for example, as follows. The patient with PCOS determine the AMH level in the blood, and increase it by no more than 1/3 from the top border of norm predict positive menstrual response to treatment with Metformin and/or weight loss. The way the illustration is by the following clinical examples. Example 1. Patient A., 19 years. Complaint: violation of the menstrual cycle (2 of the menstrual cycle for 6 months), overweight since childhood. Objective: height 170 cm, weight 109,4 kg, body mass index (BMI) of 37.9 kg/m2. Hirsute number 9 points (on a scale Ferriman-Gallwey). Pelvic ultrasound: the Right ovary 4,2*1,8*2.0 cm, left ovary 2,8*1,5*1.8 cm, each containing more than 12-13 follicles with a diameter up to 9 mm in the scan, anovulation. According to hormonal tests: Testosterone total - 2.3 nmol/L. Globulin that binds sex hormones and 11.8 nmol/L. Index of free androgens is 19.5%. Antimullerian hormone - 5,51 ng/ml. Diagnosis: polycystic ovary syndrome. The AMH level<8,1 ng/ml allows to predict the effective treatment of weight loss and Metformin. Treatment: Metformin 850 mg 2 times a day, a low-calorie diet and regular exercise, on the background of what happened on the weight loss of 8 kg Results: the onset of ovulation and pregnancy. Example 2. Patient C., 23 years. Complaint: violation of the menstrual cycle (1-2 menstrual cycles a year), excessive hair growth on the face and body, overweight since childhood. Objectively: Height 158 cm, weight 95 kg, body mass index (BMI) 38 kg/m2. Hirsute number 14 points (on a scale Ferriman-Gallwey). Pelvic ultrasound: the Right ovary 4,6*2,2*2.0 cm, left ovary 4,8*3,2*1.9 cm, the distance between the m contains more than 15 follicles with a diameter up to 9 mm in the scan. According to hormonal tests: Testosterone total - 2.7 nmol/L. Globulin that binds sex hormones - 33.8 nmol/L. Index of free androgens - 7,99%. Antimullerian hormone - 4,19 ng/ml. Diagnosis: polycystic ovary syndrome. The AMH level<8,1 ng/ml allows to predict effective treatment for weight loss. Treatment: low-calorie diet and regular physical activity in the background and then decreased weight 20.5 kg The result: increasing the number of menstrual cycles to 5 for 6 months. Example 3. Patient S., aged 22. Complaints: the irregularity of the menstrual cycle (4 menstrual for 6 months), excessive hair growth on the face and body. Objectively: Height 164 cm, weight 56 kg, body mass index 20,8 kg/m2. Hirsute 10 points (on a scale Ferriman-Gallwey). Pelvic ultrasound: the Right ovary 4,2*2,2*2.1 cm, left ovary 4,0*2,4*1.8 cm, each containing more than 15 follicles with a diameter up to 9 mm in the scan, anovulation with watchful waiting. According to hormonal tests: Testosterone total - 3.0 nmol/L. Globulin that binds sex hormones of 51.2 nmol/L. Index of free androgens - 5,9%. Antimullerian hormone - 6,22 ng/ml. Diagnosis: polycystic ovary syndrome. The AMH level<8,1 ng/ml allows to predict the effective treatment of Metformin. the factors treatment: Metformin 850 mg 2 times a day. Results: the onset of ovulation and restore regular menstrual cycle. Example 4. Patient, 26 years. Complaint: violation of the menstrual cycle with periods of amenorrhea (1-2 menstrual cycles a year), excessive hair growth on the face, chest, the white line of the abdomen. Objective: height 166 cm, weight 65 kg, body mass index 23.6 kg/m2. Hirsute 13 points (on a scale Ferriman-Gallwey). Pelvic ultrasound: the Right ovary 4,0*3,6*2.9 cm, left ovary 4,0*3,6*2.0 cm, each containing more than 12 follicles with a diameter up to 9 mm in the scan, anovulation. According to hormonal tests: Testosterone total - 3.1 nmol/L. Globulin that binds sex hormones - 45 nmol/L. Index of free androgens by 6.9%. Antimullerian hormone - 13,99 ng/ml. Diagnosis: polycystic ovary syndrome. The AMH level>to 8.1 ng/ml does not allow to predict the effective treatment of Metformin. Treatment: Metformin 850 mg 2 times a day. The result: the absence of menstruation for 6 months of treatment. The use of the claimed method allows high accuracy to predict the effectiveness of treatment of patients with PCOS Metformin and/or weight loss through the use of quantitative criteria forecasting. The method has high sensitivity and specificity. A method for predicting the effectiveness of l the treatment of patients with polycystic ovary syndrome Metformin and/or weight loss, characterized in that the patient determine the level antimullerian hormone and increasing by no more than 1/3 from the top border of norm predict positive menstrual response to treatment.
|